文献速递临床免疫质量管理与危急值

法国多中心评估Lumipulse G血sNfL检测并与其他四种免疫分析法比较

A French multicenter analytical evaluation of the automated Lumipulse G sNfL blood assay (Fujirebio®) and its comparison to four other immunoassays for serum neurofilament light chain assessment in clinical settings.
PubMed 文献 · Clin Chim Acta · 2024-10-23

该法国多中心研究评估了Lumipulse G自动化血sNfL检测的分析性能,并与四种其他免疫分析法比较。结果显示Lumipulse在不同实验室间sNfL均值差异有限但显著(p<0.001),批间亦有差异,CV为2.0-16.9%;各技术间sNfL值存在系统性差异,MSD和Ella高估,但所有结果显著相关(p<0.001)。结论认为Lumipulse检测值跨实验室可比,但需进一步调整以 harmonize sNfL 结果。

要点

  • Lumipulse血sNfL检测跨实验室均值差异有限但显著(p<0.001),批间亦有差异。
  • 池样本CV为2.0-16.9%,12份样本Z-score范围为-1.70至+1.71。
  • 各免疫分析法间sNfL值存在系统性差异,MSD和Ella高估,但均显著相关(p<0.001)。

核心结论

  • Lumipulse自动化检测在不同实验室产生可比的sNfL值,但需进一步调整以 harmonize sNfL 结果。
  • 生物学家和医生应意识到不同免疫分析供应商间结果的变异性。

研究设计与样本

  • 法国六家独立临床实验室参与的多中心比较研究。
  • 使用3个低(10 pg/mL)、中(30 pg/mL)、高(100 pg/mL)sNfL值池样本各6个重复,以及12份sNfL值递增的样本各1个重复。
  • 首先评估Lumipulse G血sNfL检测的分析性能,然后与四种其他免疫分析法比较:NF-light V2(Quanterix®)在SiMOA HD-X、Human NF-L(Biotechne®)在Ella、R-Plex Human Neurofilament L(MSD®)在Sector 2400、以及使用Uman Diagnostic/Quanterix®的手动ELISA。

主要发现

  • Lumipulse血检测跨中心比较显示,低、中、高池样本的sNfL均值在各城市间差异有限但显著(p<0.001),两个不同批次间亦有差异。
  • 池样本的变异系数范围为2.0%至16.9%。
  • 12份样本sNfL结果的Z-score范围为-1.70至+1.71。
  • 技术间比较显示sNfL值存在系统性差异,MSD和Ella相对其他检测高估。
  • 尽管如此,所有结果均显著相关(p<0.001)。

临床怎么用

  • 临床解读sNfL结果时应考虑不同免疫分析平台间的系统性差异,避免直接跨平台比较绝对值。
  • 使用Lumipulse检测时需注意批间和实验室间变异,必要时进行本地验证或校正。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Measurement of serum neurofilament light chain (sNfL) protein is becoming a key biomarker for many neurological diseases. Several immunoassays have been developed to meet these clinical needs, revealing significant differences in terms of variability and results. Here, we propose a French multicenter comparison of 5 sNfL assays. METHODS: 6 replicates of 3 pools with low (10 pg/mL), medium (30 pg/mL) and high (100 pg/mL) sNfL values and one replicate of 12 samples with growing sNfL values were analyzed by six independent French clinical laboratories. The analytical performances of the sNfL blood assay (Fujirebio®) on Lumipulse G were first evaluated then compared to four other immunoassays: NF-light V2 (Quanterix®) on SiMOA HD-X, Human NF-L (Biotechne®) on Ella, R-Plex Human Neurofilament L (MSD®) on Sector 2400; manual ELISA test using Uman Diagnostic/Quanterix®. RESULTS: Inter-center comparison of the Lumipulse blood assay revealed limited but significant differences in the mean sNfL values across low, medium, and high pools between each city (p < 0.001) and between the two different batches used. Coefficients of variation of pools ranged from 2.0 to 16.9 %. Z-score of sNfL results of the 12 samples ranged from -1.70 to +1.71. Inter-technique comparison showed a systematic difference of sNfL values, with a overestimation of MSD and Ella over other tests. Nonetheless, results were all significantly correlated (p < 0.001). CONCLUSION: The automated Lumipulse assay produced comparable sNfL values across laboratories; but further adjustments are needed to harmonize sNfL results. Biologists and physicians should be aware of the variability in results between different immunoassay suppliers.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Mondésert E, Schraen-Maschke S, Quadrio I, et al. A French multicenter analytical evaluation of the automated Lumipulse G sNfL blood assay (Fujirebio®) and its comparison to four other immunoassays for serum neurofilament light chain assessment in clinical settings. Clin Chim Acta. 2024. PMID: 39454987. doi:10.1016/j.cca.2024.120007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。